ABVC vs ALNY · rev $796.0K vs P/E 76, rev $1.29B
ABVC Biopharma Inc (ABVC) versus Alnylam Pharmaceuticals Inc (ALNY) — a side-by-side from cached financials, not a winner call.
ABVC Biopharma Inc (ABVC) is a biotechnology company listed on NASDAQ.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
Latest reported ABVC revenue for 2025-09-30 was $796.0K. Net income was -$1.3M. ABVC currently screens at market cap $35.9M.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
ABVC currently screens at market cap $35.9M. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Not investment advice. Open the ABVC and ALNY stock pages for the full models.
Not investment advice.